An update to 2010 guidelines
Patients with untreated or relapsed blastic plasmacytoid dendritic-cell neoplasm achieved high response rates with tagraxofusp, a novel targeted cytotoxin.
Vitamin D3 supplementation, compared with placebo, did not result in significant improvement in relapse-free or progression-free survival in two new trials.
The FLOT regimen is a new standard of care for patients who can tolerate triplet chemotherapy.
Disease-free survival was longer with maintenance azacitidine than with observation in older patients who responded to induction chemotherapy.
Survival was not improved with DA-EPOCH-R in patients with newly diagnosed disease.
Dual-targeted HER2 therapy had a modest signal of activity in patients with chemotherapy-refractory KRAS wild-type disease.
Overall survival was improved with pembrolizumab versus chemotherapy, but only in patients with tumor proportion score ≥50%. However, the FDA has surprisingly expanded the indication for frontline pembrolizumab to include all patients with TPS ≥1%.
Endoscopic ultrasound–guided sampling of perivascular soft-tissue cuffing identified metastases that were not found by CT or MRI in more than a quarter of patients.
The monoclonal antibody against the interleukin-5 receptor was well tolerated and effective in reducing absolute eosinophil counts in symptomatic patients.
Prof. Dr. med. Christoph Rochlitz
E-Mail: E-Mail anzeigen
In der vorliegenden Ausgabe von NEJM Journal Watch möchte ich Ihnen gerne wieder einige rezent publizierte Studien aus dem Bereich Onkologie/Hämatologie näherbringen.
Metastasis-free survival was significantly longer with apalutamide than with placebo.
Contrary to prior findings, adding olaparib to paclitaxel failed to improve survival in patients with disease progression following chemotherapy.
Assessment of tumor mutation burden using targeted next-generation sequencing may be predictive of benefit from PD-1 and PD-L1 inhibitors.
Outcomes were not superior with 5 versus 2.5 years of extended letrozole therapy.
Overall survival was significantly shorter among MGUS patients than among a matched control population in a long-term follow-up study.
Survival is similar between BRCA mutation carriers versus those with sporadic disease.
Adding tumor-treating electrical-field therapy to maintenance temozolomide chemotherapy significantly improved survival in patients with newly diagnosed glioblastoma.
Overall survival was not improved with the PD-L1 inhibitor atezolizumab versus chemotherapy in patients with highest PD-L1 expression.
First-line therapy demonstrated antitumor activity in a phase II study.
Disease-free survival is significantly improved in patients who restart therapy versus those who do not restart after discontinuation.